Analysis and data insight

Market performance

Biopharmaceutical sector emerges from its slumber in October

November 11, 2019

It appears that the spirit of giving has come early, with leading biopharmaceutical companies providing investors with a surprise present of a significant jump in their share prices in October. The reversal in the sector's fortunes was catalyzed by an outpouring of positive news, including strong third-quarter financial results that has spilled over into early November.

Money raised by biotech: 2019 vs. 2018

November 11, 2019

No Comments

Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

PROTAC attack joins molecular glue for protein degradation

November 11, 2019

By Anette Breindl

No Comments

BOSTON – At the AACR-NCI-EORTC Molecular Targets meeting in October, speakers in the second plenary session gave examples both of how far protein degradation has come as a pharmacological approach, and how far it could still go.

Biopharma money raised: Jan. 1 - Nov. 7, 2019

November 11, 2019

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Week in review

November 11, 2019

No Comments

Arkuda Therapeutics, a new company targeting progranulin and lysosomal biology to treat neurodegenerative diseases, has completed a $44 million series A financing.

Word on the street

November 11, 2019

No Comments

"Global approval doesn't mean Australia approval. Government needs a new way of valuing the benefit of therapies that are a one-off cure differently than other drugs."

Week in Washington

November 11, 2019

No Comments

President Donald Trump has officially nominated Stephen Hahn to the position of FDA commissioner, a position held on an interim basis by Ned Sharpless since April. Hahn has held the position of CEO of the MD Anderson Cancer Center in Houston since May 2018.